EP0003089A1 - Trockner für durch Siebdruck bedruckte Bogen - Google Patents

Trockner für durch Siebdruck bedruckte Bogen Download PDF

Info

Publication number
EP0003089A1
EP0003089A1 EP78400265A EP78400265A EP0003089A1 EP 0003089 A1 EP0003089 A1 EP 0003089A1 EP 78400265 A EP78400265 A EP 78400265A EP 78400265 A EP78400265 A EP 78400265A EP 0003089 A1 EP0003089 A1 EP 0003089A1
Authority
EP
European Patent Office
Prior art keywords
rack
sheet
dryer
support
sheets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78400265A
Other languages
English (en)
French (fr)
Other versions
EP0003089B1 (de
Inventor
Bernard David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SILIUM FRANCAISE A RESPONSABILITE Ltee Ste
SILIUM SARL
Original Assignee
Silium Francaise A Responsabilite Ltee Ste
SILIUM SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0003089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silium Francaise A Responsabilite Ltee Ste, SILIUM SARL filed Critical Silium Francaise A Responsabilite Ltee Ste
Publication of EP0003089A1 publication Critical patent/EP0003089A1/de
Application granted granted Critical
Publication of EP0003089B1 publication Critical patent/EP0003089B1/de
Expired legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Definitions

  • the present invention relates to a dryer for sheets printed by screen printing.
  • the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
  • a first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. At the exit of the tunnel, the leaves are dry and are removed from the machine.
  • a second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed.
  • This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place.
  • Another drawback of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
  • the object of the invention is to remedy these drawbacks by producing a dryer of the aforementioned second type, that is to say comprising an endless conveyor carried by a frame and to which are fixed racks adapted to receive the sheets, as well as 'an air blowing device on them to dry them while they are moving on the conveyor.
  • the dryer comprises a system of clips for mooring each sheet on its support rack, associated with means for automatically opening and closing these clips at the end of the drying cycle of a sheet, to allow the removal of the latter from the dryer.
  • the sheets are securely moored to their support racks, and do not tend to slide when the racks pivot at one or the other end of the dryer.
  • each set of pliers for holding a sheet on its rack consists of a row of bent blades, rotatably mounted around axes parallel to the adjoining side of the rack, and these blades are resiliently urged towards the sheet by return members to keep the sheet applied against the rack.
  • each sheet is therefore firmly held applied to the associated rack by this row of bent blades, which are automatically raised at the end of the cycle by the aforementioned automatic opening device, which is arranged to cause this opening only when the sheets are horizontal.
  • These can thus be gripped by mechanical means known per se to be removed from the dryer, without having previously slipped on the rack.
  • a dryer for sheets printed by screen printing comprising an endless conveyor 1, constituted in a manner known per se by two chains such as 2 rotating in parallel vertical planes, around terminal axes 3 superimposed, to which are toothed wheels 4.
  • This conveyor 1 is carried by a frame 5 in the middle of which is arranged a device 6 for blowing air of a type known per se.
  • a set of racks 7 constituted by rectangular frames intended to each receive a printed sheet to be dried.
  • Each rack 7 is fixed by its frame to the two chains of the conveyor.
  • a suitable system allows them to be tilted by about 25 degrees in the upper part of the dryer, while remaining vertical in the lower part.
  • the racks with their printed sheets to be dried are introduced into the dryer by the left end in FIG. 1, rotate around the right end passing through a cover visible in FIG. 1, then return under the conveyor 1 to the entrance of the dryer to be removed after being dried by the forced air coming from the device 6.
  • the path followed by the racks 7 is symbolized by the arrows shown in FIG. 2.
  • the dryer comprises for each rack 7, a system of clamps 9 for mooring each sheet 11 on its support rack 7, associated with means for automatically opening and closing these clamps 9 at the end of the cycle for drying a sheet 11, in order to allow the latter to be removed from the dryer by a device not shown.
  • Each set of pliers 9 is thus constituted, in the example shown, by a rsnged of bent blades 12 (FIG. 3), rotatably mounted around pins or pins 13 parallel to the adjoining side of the rack 7, secured to the endless conveyor 1.
  • the blades 12, preferably metallic, are bent in the example shown by forming an angle of approximately 120 degrees, the axes 13 being placed inside this angle, and supporting the blades 12 by means of ears 14 integral with the blades and in which the pins 13 are threaded.
  • the bent blades 12 are resiliently biased towards the sheet 11 by return members, to keep the sheet 11 applied against the rack 7.
  • the elastic return member of each clamp 9 is a spring wire 15 wound around the axis 13 between the two ears 14, and one end 15a of which rests under the edge 8 of the rack 7, while its other end 15b is in abutment against a corresponding part of the bent blade 12.
  • the wire spring 15 thus exerts on the branch of the blade 12 with which it is in contact by its end 15b, an elastic stress tending to rotate this blade 12 around the axis 1.3 towards the rack 7, as indicated by the arrows f in FIG. 3.
  • This elastic torque is transmitted to the sheet 11 by a helical spring 16 fixed to the end of the branch of the bent blade 12 situated opposite the rack 7, this spring 16 being applied against the sheet 11 under the action of the spring wire 15.
  • the profiled edge 8 is part of the metal frame constituting the rack 7, and it is made in S so that one of its small branches 8a is substantially parallel to the surface of the rack 7, and serves as a stop for the blade 12, by limiting the magnitude of the elastic clamping force applied to the sheet 11 by the blade 12 and its associated spring 16.
  • each set of pliers 9 carried by axes 13, comprise, in the embodiment shown in Figure 3, a series of heads such as 17, arranged to cooperate with the bent blades 12 and secured with a transverse support 18 carried by the chassis of the dryer.
  • the support 18 consists of a tubular member arranged transversely and whose axis 24 is parallel to the rods 13, in the vicinity of the inlet end of the conveyor 1.
  • the row of heads 17 is secured to the support 18 by rods 19 welded to the heads 17 and to the support 18.
  • the latter is further provided with a transverse arm 21 capable of cooperating with a member for operating the support 18 in rotation about its axis, this member being here a jack 22.
  • the rod 23 thereof can thus, when actuated, rotate the arm 21, and therefore the support 18 and all of the heads 17 in parallel vertical planes, around the transverse axis 24 of the support 18, to bring the heads 17 from the position shown in FIG. 3 to a position bringing the heads 17 into contact with the blades 12 of the rack 7 shown horizontally, until the pliers of this rack 7 are opened - Or a rotation of the support 18 in the case shown in Figure 3, of about 21 degrees counterclockwise.
  • the sequence of automatic opening and closing of a clamp 9 takes place in the following manner.
  • the rod 23 of the jack 22 rises, and pivots the support 18 which drives the head 17 and causes the opening of the clamps 9, by pressing the heads 17 on the associated blades 12, this pressure coming from the action of the wires springs 15.
  • the blade 12 and its spring 16 rock around the axis 13 and gradually move away from the sheet 11 and the rack 7.
  • the aforementioned means not shown remove the sheet in a manner known per se i1 of its support rack.
  • the clamping system produced according to the invention advantageously makes it possible to securely hold the sheets to be dried throughout the duration of their drying cycle, and in particular at the end thereof, when the sheets rotate horizontally to be removed from the machine. They therefore do not risk coming off or sliding towards the outside of the rack before being gripped by the gripping and removing device.
  • the essential advantage of the dryer according to the invention lies in the fact that the solid fixing of each sheet makes it possible to blow a large flow of ambient air thereon, instead of hot air as in carpet tunnels. This eliminates all heating energy, which significantly reduces the operating cost.
  • the invention is not limited to the embodiment described and may include alternative embodiments.
  • the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the heads 17 and on which the clamps would come. '' open when reaching horizontal.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
EP19780400265 1978-01-06 1978-12-27 Trockner für durch Siebdruck bedruckte Bogen Expired EP0003089B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie
FR7800305 1978-01-06

Publications (2)

Publication Number Publication Date
EP0003089A1 true EP0003089A1 (de) 1979-07-25
EP0003089B1 EP0003089B1 (de) 1981-08-12

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19780400265 Expired EP0003089B1 (de) 1978-01-06 1978-12-27 Trockner für durch Siebdruck bedruckte Bogen

Country Status (3)

Country Link
EP (1) EP0003089B1 (de)
DE (1) DE2860970D1 (de)
FR (1) FR2413974A1 (de)

Cited By (418)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
WO1999028462A2 (en) 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6121428A (en) * 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6270987B1 (en) 1997-01-31 2001-08-07 Genentech, Inc. O-fucosyltransferase
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
WO2004039941A2 (en) 2002-05-02 2004-05-13 The Queen's Medical Center METHODS OF SCREENING FOR TRPM4b MODULATORS
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
US6746668B2 (en) 1996-01-09 2004-06-08 Genentech, Inc. Apo-2 ligand
US6764679B2 (en) 1997-09-18 2004-07-20 Genentech, Inc. Antibodies to DcR3 Polypeptide, a TNFR Homolog
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004112572A2 (en) 2003-06-13 2004-12-29 University Of Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
WO2005014818A1 (ja) 2003-08-08 2005-02-17 Perseus Proteomics Inc. 癌高発現遺伝子
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
WO2006108273A1 (en) 2005-04-11 2006-10-19 National Research Council Of Canada Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
US7235633B2 (en) 2000-03-21 2007-06-26 Genentech, Inc. Cytokine receptors and nucleic acids encoding the same
WO2007092431A2 (en) 2006-02-06 2007-08-16 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
EP1820859A2 (de) 1998-12-22 2007-08-22 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
WO2008036135A2 (en) 2006-06-01 2008-03-27 Genentech, Inc. Crystal structure of crig and c3b: crig complex
WO2008060776A2 (en) 2006-10-03 2008-05-22 University Of Medicine And Dentistry Of New Jersey Atap peptides, nucleic acids encoding the same and associated methods of use
EP1944317A2 (de) 2000-09-01 2008-07-16 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
EP1947119A2 (de) 1997-12-12 2008-07-23 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einen chemotherapeutischen Mitteln
EP1950300A2 (de) 1998-11-18 2008-07-30 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
EP1953173A1 (de) 1999-06-15 2008-08-06 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP1967587A1 (de) 1997-10-10 2008-09-10 Genentech, Inc. APO-3-Liganden
EP2000482A1 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2011873A2 (de) 1994-05-27 2009-01-07 Genentech, Inc. Tumornekrosefaktorrezeptor-assoziierte Faktoren
EP2014298A2 (de) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP2014675A1 (de) 2003-08-11 2009-01-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2014303A2 (de) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L-Rezeptorantagonisten und CPT-11-Synergismus
EP2014677A1 (de) 1997-11-21 2009-01-14 Genentech, Inc. Mit A33 vewandte Antigene und deren pharmazeutische Verwendung
EP2033970A2 (de) 1997-10-29 2009-03-11 Genentech, Inc. WNT-1-induzierbare Gene
EP2042597A1 (de) 2000-06-23 2009-04-01 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
WO2009046123A2 (en) 2007-10-02 2009-04-09 Genentech, Inc. Nlrr-1 antagonists and uses thereof
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
WO2009079649A1 (en) 2007-12-18 2009-06-25 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2077276A1 (de) 2000-06-23 2009-07-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2083018A2 (de) 2003-04-16 2009-07-29 Genentech, Inc. Zusammensetzungen und Verfahren mit Bezug zu STOP-1
WO2009101479A2 (en) 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
EP2110434A1 (de) 2002-02-25 2009-10-21 Genentech, Inc. Typ-1 Cytokine Rezeptor GLM-R
EP2112167A2 (de) 1999-06-25 2009-10-28 Genentech, Inc. Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
EP2116551A1 (de) 2002-09-11 2009-11-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2116265A2 (de) 2000-10-12 2009-11-11 Genentech, Inc. Niederviskose konzentrierte Proteinformulierungen
WO2009140684A2 (en) 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
EP2143438A1 (de) 2001-09-18 2010-01-13 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
WO2010029513A2 (en) 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP2221316A1 (de) 2005-05-05 2010-08-25 Duke University CD19-Antikörper-Therapie für Autoimmunerkrankungen
EP2228446A1 (de) 1999-12-01 2010-09-15 Genentech, Inc. Sekretierte und transmembrane Polypeptide, sowie dafür codierende Nukleinsäuren
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2248829A1 (de) 2003-05-30 2010-11-10 Genentech, Inc. Behandlung mit Anti-VEGF Antikörpern
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
EP2258848A1 (de) 1999-12-23 2010-12-08 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP2261367A2 (de) 2007-11-29 2010-12-15 Genentech, Inc. Expressionsmarker für entzündliche darmkrankheiten
EP2263692A1 (de) 2002-12-24 2010-12-22 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
EP2263691A1 (de) 2002-07-15 2010-12-22 Genentech, Inc. Behandlung von Krebs mit dem rekombinanten, humanisierten, monoklonalen Anti-ERBB2-Antikörper 2C4 (rhuMAb 2C4)
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2267450A2 (de) 2005-04-29 2010-12-29 The Regents of the University of California Antikörper gegen Histonmodifikationen für die klinische Diagnose und Prognose von Krebs
EP2272868A2 (de) 2003-06-05 2011-01-12 Genentech, Inc. Kombinationstherapie für B-Zell-Erkrankungen
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
EP2277908A2 (de) 2003-07-08 2011-01-26 Genentech, Inc. Heterologe IL-17A/F-Polypeptide, Antikörper und deren therapeutische Verwendungen
WO2011011339A1 (en) 2009-07-20 2011-01-27 Genentech, Inc. Gene expression markers for crohn's disease
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP2292301A2 (de) 2001-02-22 2011-03-09 Genentech, Inc. Anti-Interferon-alpha-Antikörper
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
WO2011031397A1 (en) 2009-08-06 2011-03-17 Genentech, Inc. Method to improve virus removal in protein purification
EP2298807A2 (de) 2004-07-30 2011-03-23 Rinat Neuroscience Corp. Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
EP2301568A1 (de) 2003-11-17 2011-03-30 Genentech, Inc. Antikörper gegen IRTA2 für die Behandlung von hämatopoetischen Tumoren
EP2305817A2 (de) 2000-08-07 2011-04-06 Centocor Ortho Biotech Inc. Antikörper gegen IL-12, Zusammensetzungen, Verfahren und Verwendungen
EP2305711A2 (de) 2005-04-11 2011-04-06 Rinat Neuroscience Corp. Verfahren zur Schmerzbehandlung von Osteoarthritis durch Verabreichung eines NGF-Antagonisten sowie diese enthaltende Zusammensetzungen
EP2308968A1 (de) 2002-11-26 2011-04-13 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
EP2308888A1 (de) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anti-IL-6-Antikörper, Zusammensetzungen, Verfahren und Anwendungen
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2311960A2 (de) 2001-08-29 2011-04-20 Genentech, Inc. Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität
WO2011046515A1 (en) 2009-10-14 2011-04-21 Nanyang Technological University Antiproliferative agent
EP2314318A1 (de) 2001-01-31 2011-04-27 Biogen Idec Inc. CD80 Antikörper in Kombination mit Chemotherapeutikum zur Behandlung von neoplastischen Erkrankungen der B Zellen
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
EP2319929A1 (de) 1998-12-23 2011-05-11 Genentech, Inc. Mit IL-1 in Zusammenhang stehende Polypeptide
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
EP2322202A2 (de) 2002-10-29 2011-05-18 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
EP2325208A1 (de) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiqutin Antikörper
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2330129A2 (de) 2000-08-07 2011-06-08 Centocor Ortho Biotech Inc. Antikörper gegen TNF, Zusammensetzungen, Verfahren und Verwendungen
EP2332996A1 (de) 2002-09-11 2011-06-15 Genentech, Inc. Proteinreinigung
EP2333069A2 (de) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutische Verwendungen von IL-17 homologe Polypeptide
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2336178A1 (de) 2003-12-11 2011-06-22 Genentech, Inc. Verfahren und Produkt um c-Met-Dimerisierung und -Aktivierung zu verhindern
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
EP2340849A1 (de) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF Antikörper zur Behandlung verschiedener Beschwerden
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP2361931A1 (de) 2004-07-20 2011-08-31 Genentech, Inc. Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011104687A1 (en) 2010-02-24 2011-09-01 Rinat Neuroscience Corporation Antagonist anti-il-7 receptor antibodies and methods
EP2364716A2 (de) 2002-11-08 2011-09-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
EP2364997A2 (de) 1999-01-15 2011-09-14 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP2366716A2 (de) 2006-03-21 2011-09-21 Genentech, Inc. Kombinationstherapie mit Alpha5beta1-Antagonisten
WO2011119888A2 (en) 2010-03-24 2011-09-29 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2371388A2 (de) 2004-10-20 2011-10-05 Genentech, Inc. Antikörperformulierungen
WO2011123507A1 (en) 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
EP2380592A2 (de) 2005-11-14 2011-10-26 Rinat Neuroscience Corp. Antagonisten-Antikörper gegen calcitonin-Gen-related-Peptid und Verfahren damit
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (de) 2002-02-22 2011-11-23 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2389951A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2390666A1 (de) 2006-03-21 2011-11-30 The Regents of The University of California N-Cadherin als Ziel für die Krebsdiagnose und -therapie
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011150110A1 (en) 2010-05-25 2011-12-01 Genentech, Inc. Methods of purifying polypeptides
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2011159655A2 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2399605A1 (de) 2005-02-23 2011-12-28 Genentech, Inc. Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
EP2402373A2 (de) 2006-01-05 2012-01-04 Genentech, Inc. ANTI-EPHB4-Antikörper sowie Verfahren zu deren Verwendung
EP2402756A2 (de) 2003-12-23 2012-01-04 Rinat Neuroscience Corp. Agonistische anti-trkC-AntiKörper und Verfahren zur Verwendung davon
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
EP2423333A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
WO2012027723A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc Notum protein modulators and methods of use
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2434022A2 (de) 2002-10-03 2012-03-28 Genentech, Inc. Verwendung von A33-Antigenen und JAM-IT
EP2436781A1 (de) 2007-02-22 2012-04-04 Genentech, Inc. Verfahren für den Nachweis von entzündlicher Darmerkrankung
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2444409A2 (de) 2002-09-16 2012-04-25 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2447282A2 (de) 2006-05-30 2012-05-02 Genentech, Inc. Antikörper gegen CD22, Immunkonjugate sowie ihre Verwendungen
EP2450050A1 (de) 2006-11-29 2012-05-09 Genentech, Inc. Heterodimere IL-17A/F-Polypeptide und ihre therapeutische Verwendung
WO2012058768A1 (en) 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2452694A1 (de) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendung
EP2455404A2 (de) 2006-08-22 2012-05-23 G2 Inflammation Pty Ltd Anti-C5AR-Antikörper mit verbesserten Eigenschaften
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012078813A2 (en) 2010-12-08 2012-06-14 Stem Centrx, Inc. Novel modulators and methods of use
EP2471809A1 (de) 2006-07-11 2012-07-04 University Of Medicine And Dentistry Of New Jersey Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2474557A2 (de) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012112943A1 (en) 2011-02-18 2012-08-23 Stem Centrx, Inc. Novel modulators and methods of use
EP2500438A2 (de) 2002-09-25 2012-09-19 Genentech, Inc. Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
WO2012125614A1 (en) 2011-03-15 2012-09-20 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
EP2520935A2 (de) 2006-08-09 2012-11-07 Homestead Clinical Corporation Organspezifische Proteine und Verfahren zu deren Verwendung
EP2526960A1 (de) 2003-03-12 2012-11-28 Genentech, Inc. Verwendung von BV8 und/oder EG-VEGF zum Fördern der Hämatopoiese
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
EP2548577A1 (de) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Humane Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendungen
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2567975A2 (de) 2006-11-21 2013-03-13 The Regents of The University of California Modulation von RHAMM (CD168) zur selektiven Fettgewebeentwicklung
EP2573114A1 (de) 2005-08-10 2013-03-27 MacroGenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
EP2586788A1 (de) 2007-07-09 2013-05-01 Genentech, Inc. Verhindern der Disulfid-Bindungsreduktion während der rekombinanten Herstellung von Polypeptiden
WO2013067301A1 (en) 2011-11-02 2013-05-10 Genentech, Inc. Overload and elute chromatography
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2592156A2 (de) 2007-06-08 2013-05-15 Genentech, Inc. Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
WO2013068946A2 (en) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2013093707A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2614839A2 (de) 2006-04-05 2013-07-17 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2623516A2 (de) 2005-12-02 2013-08-07 Genentech, Inc. Zusammensetzungen und Verfahren für die Behandlung von Krankheiten und Leiden in Zusammenhang mit der Zytokinsignalisierung sowie unter Verwendung an IL-22 und IL-22R bindender Antikörper
EP2639301A2 (de) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynukleotide zur Kodierung neuartiger PCSK9-Varianten
EP2641618A2 (de) 2007-07-16 2013-09-25 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
WO2013149111A2 (en) 2012-03-29 2013-10-03 Novimmune S.A. Anti-tlr4 antibodies and uses thereof
EP2657253A2 (de) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b-Antikörper und Immunokonjugate sowie Verwendungsverfahren
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
EP2679600A1 (de) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3-Antikörper und Verwendungsverfahren dafür
WO2014018554A1 (en) 2012-07-23 2014-01-30 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
EP2703011A2 (de) 2007-05-07 2014-03-05 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
WO2014087248A2 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
WO2014130064A1 (en) 2013-02-22 2014-08-28 Abbvie Inc. Ultrafiltration and diafiltration formulation methods for protein processing
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
WO2014144061A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014172661A1 (en) 2013-04-19 2014-10-23 The Regent Of The University Of California Lone star virus
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP2842968A1 (de) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anti-IL-6-Antikörper, Zusammensetzungen, Verfahren und Verwendung
WO2015031837A1 (en) 2013-08-29 2015-03-05 City Of Hope Cell penetrating conjugates and methods of use thereof
EP2845866A1 (de) 2006-10-27 2015-03-11 Genentech, Inc. Antikörper und Immunkonjugate sowie ihre Verwendungen
EP2851372A1 (de) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF-Antikörper
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015084625A1 (en) 2013-12-02 2015-06-11 Baylor College Of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015095418A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2015147915A1 (en) 2013-03-24 2015-10-01 Development Center For Biotechnology Methods for suppressing cancer by inhibition of tmcc3
EP2927244A1 (de) 2008-09-19 2015-10-07 MedImmune, LLC Gegen DLL4 gerichtete Antikörper und ihre Verwendung
EP2926830A2 (de) 2010-08-31 2015-10-07 Theraclone Sciences, Inc. Antikörper zur Neutralisierung des humanen Immundefizienz-Virus (HIV)
WO2015161267A2 (en) 2014-04-18 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
WO2015195917A1 (en) 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Monoclonal antibodies against her2 epitope and methods of use thereof
WO2015195835A2 (en) 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
EP2962697A1 (de) 2006-11-27 2016-01-06 diaDexus, Inc. Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
EP2980100A1 (de) 2007-06-08 2016-02-03 Australian Poultry CRC Pty Ltd Clostridium toxin netb
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2016073794A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016092419A1 (en) 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof
EP3043181A1 (de) 2008-01-15 2016-07-13 The Board of Trustees of The Leland Stanford Junior University Marker für stammzellen von akuter myeloischer leukämie
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
WO2016164835A1 (en) 2015-04-08 2016-10-13 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
WO2016166629A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Therapeutic antibodies and their uses
CN106079858A (zh) * 2016-08-03 2016-11-09 钟晴晴 一种丝网印刷机
WO2016178779A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
EP3095797A1 (de) 2012-02-24 2016-11-23 Stemcentrx, Inc. Dll3-antikörper und verfahren zur verwendung
EP3095463A2 (de) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Verfahren zur behandlung von progressiver multipler sklerose
EP3095793A1 (de) 2003-07-28 2016-11-23 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
WO2017024238A1 (en) 2015-08-06 2017-02-09 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
EP3130349A1 (de) 2004-06-04 2017-02-15 Genentech, Inc. Verfahren zur behandlung von multipler sklerose
WO2017041004A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EP3176185A1 (de) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Herstellung von t-zellen zum retargeting von heterodimeren immunglobulinen
WO2017100714A1 (en) 2015-12-10 2017-06-15 City Of Hope Cell penetrating cyanine-coupled antibodies
WO2017112917A1 (en) 2015-12-24 2017-06-29 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
EP3189831A1 (de) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Proteinformulierungen und verfahren zur herstellung davon
WO2017125831A1 (en) 2016-01-21 2017-07-27 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3208612A1 (de) 2008-04-09 2017-08-23 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP3211008A1 (de) 2008-08-29 2017-08-30 F. Hoffmann-La Roche AG Kreuzreaktive und bispezifische anti-il-17a/f-antikörper
WO2017173302A2 (en) 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017218977A2 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
EP3260136A1 (de) 2009-03-17 2017-12-27 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP3263581A1 (de) 2005-05-17 2018-01-03 University of Connecticut Zusammensetzungen und verfahren zur immunmodulation in einem organismus
WO2018018039A2 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3279215A1 (de) 2009-11-24 2018-02-07 MedImmune Limited Gezielte bindemittel gegen b7-h1
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035025A1 (en) 2016-08-15 2018-02-22 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
WO2018048939A1 (en) 2016-09-06 2018-03-15 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
WO2018055573A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3301116A1 (de) 2008-08-25 2018-04-04 Dana Farber Cancer Institute, Inc. Konserviertes influenzahämagglutininepitop und antikörper dagegen
WO2018064478A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
WO2018064436A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
WO2018083535A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
EP3321283A1 (de) 2008-06-13 2018-05-16 Pfizer Inc Behandlung von chronischer prostatitis
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
EP3323830A1 (de) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anti-gd2-antikörper
WO2018093841A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il-23 specific antibody
EP3327039A1 (de) 2010-06-02 2018-05-30 Dana Farber Cancer Institute, Inc. Humanisierte monoklonale antikörper und verfahren zu ihrer verwendung
EP3333187A1 (de) 2007-12-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Antikörper gegen influenzavirus und verfahren zur verwendung davon
EP3338793A1 (de) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Neuartige sez6-modulatoren und verfahren zur verwendung
US10011658B2 (en) 2015-04-03 2018-07-03 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3348277A1 (de) 2009-11-20 2018-07-18 The Regents of The University of California Epithelialmembranenprotein-2 (emp2) und proliferative vitreoretinopathie (pvr)
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
EP3360567A1 (de) 2007-11-07 2018-08-15 Genentech, Inc. Amp zur verwendung in der behandlung von mikrobiellen erkrankungen
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2018194496A2 (ru) 2017-04-17 2018-10-25 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3401335A1 (de) 2008-01-30 2018-11-14 Genentech, Inc. Zusammensetzung mit einem an her2-domäne ii bindenden antikörper und saure varianten davon
WO2018209194A2 (en) 2017-05-12 2018-11-15 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
EP3412309A1 (de) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Verfahren zur verabreichung von beta7-integrin-antagonisten
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
EP3447075A2 (de) 2015-05-15 2019-02-27 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
WO2019070164A1 (ru) 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EP3495814A2 (de) 2013-03-27 2019-06-12 F. Hoffmann-La Roche AG Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
EP3511344A1 (de) 2004-12-10 2019-07-17 NovImmune S.A. Neutralisierende antikörper und verfahren zur verwendung davon
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
EP3524620A1 (de) 2008-10-14 2019-08-14 Genentech, Inc. Immunglobulinvarianten und ihre verwendung
EP3536699A1 (de) 2013-07-12 2019-09-11 F. Hoffmann-La Roche AG Darstellung einer eingabeoptimierung in der ionenaustauschchromatografie
WO2019171252A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2019175658A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
WO2019178248A1 (en) 2018-03-13 2019-09-19 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
EP3578569A1 (de) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
EP3587450A1 (de) 2007-12-17 2020-01-01 Pfizer Limited Behandlung von interstitieller cystitis mit ngf inhibitoren
WO2020006568A1 (en) 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020018789A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
EP3604523A1 (de) 2001-12-28 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung von proteinen
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
EP3613433A1 (de) 2014-05-30 2020-02-26 Henlix Biotech Co., Ltd. Antikörper gegen den epidermalen wachstumsfaktor-rezeptor (egfr)
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
WO2020096959A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
EP3653641A1 (de) 2004-02-19 2020-05-20 Genentech, Inc. Antikörper mit korrigiertem cdr
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
EP3699196A1 (de) 2014-10-06 2020-08-26 Dana Farber Cancer Institute, Inc. Humanisierte antikörper des cc-chemokin-rezeptors 4 (ccr4) und verfahren zur verwendung davon
EP3705494A2 (de) 2013-08-14 2020-09-09 Sachdev Sidhu Antikörper gegen frizzled proteine und verwendung davon
WO2020213724A1 (ja) 2019-04-19 2020-10-22 中外製薬株式会社 抗体改変部位認識キメラ受容体
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2020247634A1 (en) 2019-06-05 2020-12-10 Genentech, Inc. A method for regeneration of an overload chromatography column
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
WO2021021605A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
EP3789036A1 (de) 2013-07-16 2021-03-10 F. Hoffmann-La Roche AG Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und tigit-inhibitoren
EP3795168A1 (de) 2015-01-16 2021-03-24 City of Hope Zellendurchdringende antikörper
EP3842448A1 (de) 2015-05-15 2021-06-30 City of Hope Chimäre antigenrezeptorzusammensetzungen
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP3862365A1 (de) 2016-01-08 2021-08-11 F. Hoffmann-La Roche AG Verfahren zur behandlung von cea-positiven karzinomen unter verwendung von antagonisten mit pd-1-achsen-bindung und bispezifischen anti-cea-/anti-cd3-antikörpern
WO2021163265A1 (en) 2020-02-11 2021-08-19 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
EP3892294A1 (de) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021222935A2 (en) 2020-04-28 2021-11-04 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
US11241417B2 (en) 2018-06-21 2022-02-08 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022159349A1 (en) 2021-01-20 2022-07-28 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
WO2022190034A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2022190033A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022200387A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022200389A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
EP4137518A1 (de) 2013-02-06 2023-02-22 Inhibrx, Inc. Nicht-plättchen-depletierende und nicht-erythrozyten-depletierende cd47-antikörpern und verfahren zur verwendung davon
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023081471A1 (en) 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
EP4219560A2 (de) 2010-02-18 2023-08-02 The Regents of The University of California Integrin alpha v beta 8 neutralisierender antikörper
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023192622A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
WO2023187407A1 (en) 2022-04-01 2023-10-05 Bradcode Limited Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
EP4324481A2 (de) 2014-03-21 2024-02-21 Teva Pharmaceuticals International GmbH Antagonistische antikörper gegen calcitonin-gen-assoziiertes peptid und verfahren zur verwendung davon
EP4339615A2 (de) 2016-09-16 2024-03-20 Shanghai Henlius Biotech, Inc. Anti-pd-1-antikörper
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
KR101551295B1 (ko) 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
CN104870056A (zh) 2012-10-05 2015-08-26 弗·哈夫曼-拉罗切有限公司 用于诊断和治疗炎性肠病的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Cited By (558)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011873A2 (de) 1994-05-27 2009-01-07 Genentech, Inc. Tumornekrosefaktorrezeptor-assoziierte Faktoren
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6746668B2 (en) 1996-01-09 2004-06-08 Genentech, Inc. Apo-2 ligand
US7285533B2 (en) 1996-01-09 2007-10-23 Genentech, Inc. Apo-2 ligand
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6492139B1 (en) 1996-09-30 2002-12-10 Genentech, Inc. Vertebrate smoothened proteins
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US6407216B1 (en) 1996-09-30 2002-06-18 Genentech, Inc. Vertebrate smoothened antibodies
US6270987B1 (en) 1997-01-31 2001-08-07 Genentech, Inc. O-fucosyltransferase
US6716598B2 (en) 1997-06-13 2004-04-06 Genentech, Inc. Protein recovery
US6121428A (en) * 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
US6322997B1 (en) 1997-06-13 2001-11-27 Genentech, Inc. Protein recovery
US6764679B2 (en) 1997-09-18 2004-07-20 Genentech, Inc. Antibodies to DcR3 Polypeptide, a TNFR Homolog
EP1967587A1 (de) 1997-10-10 2008-09-10 Genentech, Inc. APO-3-Liganden
EP2033970A2 (de) 1997-10-29 2009-03-11 Genentech, Inc. WNT-1-induzierbare Gene
EP2014677A1 (de) 1997-11-21 2009-01-14 Genentech, Inc. Mit A33 vewandte Antigene und deren pharmazeutische Verwendung
WO1999028462A2 (en) 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
EP1947119A2 (de) 1997-12-12 2008-07-23 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einen chemotherapeutischen Mitteln
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
EP2333069A2 (de) 1998-05-15 2011-06-15 Genentech, Inc. Therapeutische Verwendungen von IL-17 homologe Polypeptide
EP1950300A2 (de) 1998-11-18 2008-07-30 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
EP1820859A2 (de) 1998-12-22 2007-08-22 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
EP2319929A1 (de) 1998-12-23 2011-05-11 Genentech, Inc. Mit IL-1 in Zusammenhang stehende Polypeptide
EP2330198A1 (de) 1998-12-23 2011-06-08 Genentech, Inc. Mit IL-1 in Zusammenhang stehende Polypeptide
EP2364997A2 (de) 1999-01-15 2011-09-14 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
EP2386574A2 (de) 1999-01-15 2011-11-16 Genentech, Inc. Polypeptid Variante mit geänderter Effektorwirkung
EP2366713A2 (de) 1999-01-15 2011-09-21 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
EP1956030A1 (de) 1999-06-15 2008-08-13 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP1953173A1 (de) 1999-06-15 2008-08-06 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP2112167A2 (de) 1999-06-25 2009-10-28 Genentech, Inc. Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US10160811B2 (en) 1999-08-27 2018-12-25 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7371379B2 (en) 1999-08-27 2008-05-13 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US10280228B2 (en) 1999-08-27 2019-05-07 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP2110138A1 (de) 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
EP2111870A1 (de) 1999-08-27 2009-10-28 Genentech, Inc. Dosierung für die Behandlung mit Anti-ErbB2-Antikörpern
EP2228446A1 (de) 1999-12-01 2010-09-15 Genentech, Inc. Sekretierte und transmembrane Polypeptide, sowie dafür codierende Nukleinsäuren
EP2258848A1 (de) 1999-12-23 2010-12-08 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP2290081A2 (de) 1999-12-23 2011-03-02 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US7939650B2 (en) 2000-01-13 2011-05-10 Genentech, Inc. Stra6 polypeptides
US7855278B2 (en) 2000-01-13 2010-12-21 Genentech, Inc. Antibodies to Stra6 polypeptides
US7741439B2 (en) 2000-01-13 2010-06-22 Genentech, Inc. Isolated stra6 polypeptides
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
US7235633B2 (en) 2000-03-21 2007-06-26 Genentech, Inc. Cytokine receptors and nucleic acids encoding the same
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2042597A1 (de) 2000-06-23 2009-04-01 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2077276A1 (de) 2000-06-23 2009-07-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2014303A2 (de) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L-Rezeptorantagonisten und CPT-11-Synergismus
EP2330129A2 (de) 2000-08-07 2011-06-08 Centocor Ortho Biotech Inc. Antikörper gegen TNF, Zusammensetzungen, Verfahren und Verwendungen
EP3597752A1 (de) 2000-08-07 2020-01-22 Janssen Biotech, Inc. Anti-il-12-antikörper, zusammensetzungen, verfahren und verwendungen
EP2305817A2 (de) 2000-08-07 2011-04-06 Centocor Ortho Biotech Inc. Antikörper gegen IL-12, Zusammensetzungen, Verfahren und Verwendungen
EP3118318A1 (de) 2000-08-07 2017-01-18 Janssen Biotech, Inc. Anti-tnf-antikörper, zusammensetzungen, verfahren und verwendungen
EP2014298A2 (de) 2000-08-24 2009-01-14 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A2 (de) 2000-09-01 2008-07-16 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
EP2116265A2 (de) 2000-10-12 2009-11-11 Genentech, Inc. Niederviskose konzentrierte Proteinformulierungen
EP2314318A1 (de) 2001-01-31 2011-04-27 Biogen Idec Inc. CD80 Antikörper in Kombination mit Chemotherapeutikum zur Behandlung von neoplastischen Erkrankungen der B Zellen
EP2292301A2 (de) 2001-02-22 2011-03-09 Genentech, Inc. Anti-Interferon-alpha-Antikörper
EP2340849A1 (de) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF Antikörper zur Behandlung verschiedener Beschwerden
EP2000482A1 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2311960A2 (de) 2001-08-29 2011-04-20 Genentech, Inc. Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität
EP2151244A1 (de) 2001-09-18 2010-02-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2153843A1 (de) 2001-09-18 2010-02-17 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2143438A1 (de) 2001-09-18 2010-01-13 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2308888A1 (de) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anti-IL-6-Antikörper, Zusammensetzungen, Verfahren und Anwendungen
EP3604523A1 (de) 2001-12-28 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung von proteinen
EP3960855A1 (de) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung von proteinen
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2388265A1 (de) 2002-02-22 2011-11-23 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2110434A1 (de) 2002-02-25 2009-10-21 Genentech, Inc. Typ-1 Cytokine Rezeptor GLM-R
WO2004039941A2 (en) 2002-05-02 2004-05-13 The Queen's Medical Center METHODS OF SCREENING FOR TRPM4b MODULATORS
EP2263691A1 (de) 2002-07-15 2010-12-22 Genentech, Inc. Behandlung von Krebs mit dem rekombinanten, humanisierten, monoklonalen Anti-ERBB2-Antikörper 2C4 (rhuMAb 2C4)
EP2332996A1 (de) 2002-09-11 2011-06-15 Genentech, Inc. Proteinreinigung
EP3388452A2 (de) 2002-09-11 2018-10-17 Genentech, Inc. Proteinreinigung
EP2116551A1 (de) 2002-09-11 2009-11-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2444409A2 (de) 2002-09-16 2012-04-25 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2500438A2 (de) 2002-09-25 2012-09-19 Genentech, Inc. Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
EP2434022A2 (de) 2002-10-03 2012-03-28 Genentech, Inc. Verwendung von A33-Antigenen und JAM-IT
EP2322202A2 (de) 2002-10-29 2011-05-18 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
EP2322200A2 (de) 2002-10-29 2011-05-18 Genentech, Inc. Gestaltungen und Methoden für die Behandlung von immune verwandte Krankheiten
EP2322203A2 (de) 2002-10-29 2011-05-18 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
EP2322201A2 (de) 2002-10-29 2011-05-18 Genentech, Inc. Gestaltungen und Methoden für die behandlung von Immune verwandte Krankheiten
EP2364716A2 (de) 2002-11-08 2011-09-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
EP2308968A1 (de) 2002-11-26 2011-04-13 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
EP2314676A1 (de) 2002-11-26 2011-04-27 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
EP2311870A1 (de) 2002-11-26 2011-04-20 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2311868A1 (de) 2002-11-26 2011-04-20 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
EP2263692A1 (de) 2002-12-24 2010-12-22 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
EP2270048A2 (de) 2002-12-24 2011-01-05 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
EP2526960A1 (de) 2003-03-12 2012-11-28 Genentech, Inc. Verwendung von BV8 und/oder EG-VEGF zum Fördern der Hämatopoiese
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2083018A2 (de) 2003-04-16 2009-07-29 Genentech, Inc. Zusammensetzungen und Verfahren mit Bezug zu STOP-1
EP2251355A1 (de) 2003-05-30 2010-11-17 Genentech, Inc. Behandlung mit anti-VEGF Antikörpern
EP2248829A1 (de) 2003-05-30 2010-11-10 Genentech, Inc. Behandlung mit Anti-VEGF Antikörpern
EP2311875A1 (de) 2003-05-30 2011-04-20 Genentech, Inc. Behandlung mit Anti-VEGF Antikörpern
EP2272868A2 (de) 2003-06-05 2011-01-12 Genentech, Inc. Kombinationstherapie für B-Zell-Erkrankungen
WO2004112572A2 (en) 2003-06-13 2004-12-29 University Of Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
EP3594228A1 (de) 2003-07-08 2020-01-15 Genentech, Inc. Heterologe il-17a/f-polypeptide und deren therapeutische verwendungen
EP2784084A1 (de) 2003-07-08 2014-10-01 Genentech, Inc. Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen
EP2277908A2 (de) 2003-07-08 2011-01-26 Genentech, Inc. Heterologe IL-17A/F-Polypeptide, Antikörper und deren therapeutische Verwendungen
EP3722309A1 (de) 2003-07-28 2020-10-14 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
EP3095793A1 (de) 2003-07-28 2016-11-23 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
WO2005014818A1 (ja) 2003-08-08 2005-02-17 Perseus Proteomics Inc. 癌高発現遺伝子
EP2311468A1 (de) 2003-08-08 2011-04-20 Perseus Proteomics Inc. In Krebs überexprimiertes Gen
EP2014675A1 (de) 2003-08-11 2009-01-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2301568A1 (de) 2003-11-17 2011-03-30 Genentech, Inc. Antikörper gegen IRTA2 für die Behandlung von hämatopoetischen Tumoren
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
EP2336178A1 (de) 2003-12-11 2011-06-22 Genentech, Inc. Verfahren und Produkt um c-Met-Dimerisierung und -Aktivierung zu verhindern
EP2402756A2 (de) 2003-12-23 2012-01-04 Rinat Neuroscience Corp. Agonistische anti-trkC-AntiKörper und Verfahren zur Verwendung davon
EP3653641A1 (de) 2004-02-19 2020-05-20 Genentech, Inc. Antikörper mit korrigiertem cdr
EP3130349A1 (de) 2004-06-04 2017-02-15 Genentech, Inc. Verfahren zur behandlung von multipler sklerose
EP2361931A1 (de) 2004-07-20 2011-08-31 Genentech, Inc. Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
EP2298807A2 (de) 2004-07-30 2011-03-23 Rinat Neuroscience Corp. Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
EP3498294A1 (de) 2004-10-20 2019-06-19 Genentech, Inc. Antikörperformulierungen
EP2371388A2 (de) 2004-10-20 2011-10-05 Genentech, Inc. Antikörperformulierungen
EP3511344A1 (de) 2004-12-10 2019-07-17 NovImmune S.A. Neutralisierende antikörper und verfahren zur verwendung davon
EP2230517A1 (de) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
EP2548575A1 (de) 2005-02-15 2013-01-23 Duke University Anti-CD19-Antikörper die ADCC vermitteln zur Verwendung in der Behandlung von Autoimmunkrankheiten
EP2399605A1 (de) 2005-02-23 2011-12-28 Genentech, Inc. Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
EP3272358A1 (de) 2005-04-11 2018-01-24 Rinat Neuroscience Corporation Verfahren zur schmerzbehandlung von osteoarthritis durch verabreichung eines ngf-antagonisten sowie diese enthaltende zusammensetzungen
EP2305711A2 (de) 2005-04-11 2011-04-06 Rinat Neuroscience Corp. Verfahren zur Schmerzbehandlung von Osteoarthritis durch Verabreichung eines NGF-Antagonisten sowie diese enthaltende Zusammensetzungen
WO2006108273A1 (en) 2005-04-11 2006-10-19 National Research Council Of Canada Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
EP2267450A2 (de) 2005-04-29 2010-12-29 The Regents of the University of California Antikörper gegen Histonmodifikationen für die klinische Diagnose und Prognose von Krebs
EP2842968A1 (de) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anti-IL-6-Antikörper, Zusammensetzungen, Verfahren und Verwendung
EP2221316A1 (de) 2005-05-05 2010-08-25 Duke University CD19-Antikörper-Therapie für Autoimmunerkrankungen
EP3805245A1 (de) 2005-05-17 2021-04-14 University of Connecticut Zusammensetzungen und verfahren zur immunomodulation in einem organismus
EP3263581A1 (de) 2005-05-17 2018-01-03 University of Connecticut Zusammensetzungen und verfahren zur immunmodulation in einem organismus
EP2452694A1 (de) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendung
EP3501537A1 (de) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23-antikörper, zusammensetzungen, verfahren und verwendungen
EP2573114A1 (de) 2005-08-10 2013-03-27 MacroGenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
EP3069731A1 (de) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
EP2380592A2 (de) 2005-11-14 2011-10-26 Rinat Neuroscience Corp. Antagonisten-Antikörper gegen calcitonin-Gen-related-Peptid und Verfahren damit
EP3842458A1 (de) 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonistische antikörper gegen calcitoningen-assoziiertes peptid
EP3178493A1 (de) 2005-11-14 2017-06-14 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
EP3045182A1 (de) 2005-11-14 2016-07-20 Labrys Biologics Inc. Antagonisten-antikörper gegen calcitonin-gen-related-peptid und verfahren damit
US10450383B2 (en) 2005-12-02 2019-10-22 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) antibodies and methods of use thereof
US11174323B2 (en) 2005-12-02 2021-11-16 Dana-Farber Cancer Institute, Inc. Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies
US9676867B2 (en) 2005-12-02 2017-06-13 Dana-Farber Cancer Institute Inc. Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody
EP3006466A2 (de) 2005-12-02 2016-04-13 Genentech, Inc. Zusammensetzungen und verfahren für die behandlung von krankheiten und störungen in zusammenhang mit der zytokinsignalisierung, mit antikörper, die an il-22 und il-22r binden
EP2623516A2 (de) 2005-12-02 2013-08-07 Genentech, Inc. Zusammensetzungen und Verfahren für die Behandlung von Krankheiten und Leiden in Zusammenhang mit der Zytokinsignalisierung sowie unter Verwendung an IL-22 und IL-22R bindender Antikörper
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
EP2325208A1 (de) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiqutin Antikörper
EP3309170A1 (de) 2005-12-15 2018-04-18 Genentech, Inc. Polyubiquitin-antikörper
EP3219328A1 (de) 2005-12-29 2017-09-20 Janssen Biotech, Inc. Humane anti-il-23-antikörper, zusammensetzungen, verfahren und verwendungen
EP2548577A1 (de) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Humane Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendungen
EP3760230A1 (de) 2005-12-29 2021-01-06 Janssen Biotech, Inc. Humane anti-il-23-antikörper, zusammensetzungen, verfahren und verwendungen
EP2402373A2 (de) 2006-01-05 2012-01-04 Genentech, Inc. ANTI-EPHB4-Antikörper sowie Verfahren zu deren Verwendung
EP3156418A1 (de) 2006-01-05 2017-04-19 Genentech, Inc. Anti-ephb4-antikörper sowie verfahren zu deren verwendung
WO2007092431A2 (en) 2006-02-06 2007-08-16 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
EP2390666A1 (de) 2006-03-21 2011-11-30 The Regents of The University of California N-Cadherin als Ziel für die Krebsdiagnose und -therapie
EP2366716A2 (de) 2006-03-21 2011-09-21 Genentech, Inc. Kombinationstherapie mit Alpha5beta1-Antagonisten
EP2389950A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2389949A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2389947A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2389946A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2389948A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2389951A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP2614839A2 (de) 2006-04-05 2013-07-17 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
EP2446904A2 (de) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 Antikörper, Immunkonjugate sowie ihre Verwendungen
EP2447282A2 (de) 2006-05-30 2012-05-02 Genentech, Inc. Antikörper gegen CD22, Immunkonjugate sowie ihre Verwendungen
WO2008036135A2 (en) 2006-06-01 2008-03-27 Genentech, Inc. Crystal structure of crig and c3b: crig complex
EP2639301A2 (de) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynukleotide zur Kodierung neuartiger PCSK9-Varianten
EP2671946A1 (de) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynukleotide zur Kodierung neuartiger PCSK9-Varianten
EP2471815A1 (de) 2006-07-11 2012-07-04 University Of Medicine And Dentistry Of New Jersey Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
EP2471809A1 (de) 2006-07-11 2012-07-04 University Of Medicine And Dentistry Of New Jersey Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
EP2520935A2 (de) 2006-08-09 2012-11-07 Homestead Clinical Corporation Organspezifische Proteine und Verfahren zu deren Verwendung
EP2455404A2 (de) 2006-08-22 2012-05-23 G2 Inflammation Pty Ltd Anti-C5AR-Antikörper mit verbesserten Eigenschaften
EP2423333A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
EP2423332A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
WO2008060776A2 (en) 2006-10-03 2008-05-22 University Of Medicine And Dentistry Of New Jersey Atap peptides, nucleic acids encoding the same and associated methods of use
EP2845866A1 (de) 2006-10-27 2015-03-11 Genentech, Inc. Antikörper und Immunkonjugate sowie ihre Verwendungen
EP2567975A2 (de) 2006-11-21 2013-03-13 The Regents of The University of California Modulation von RHAMM (CD168) zur selektiven Fettgewebeentwicklung
EP2962697A1 (de) 2006-11-27 2016-01-06 diaDexus, Inc. Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
EP3181147A1 (de) 2006-11-29 2017-06-21 Genentech, Inc. Heterodimere il-17a/f-polypeptide und therapeutkum damit
EP2450050A1 (de) 2006-11-29 2012-05-09 Genentech, Inc. Heterodimere IL-17A/F-Polypeptide und ihre therapeutische Verwendung
EP2436781A1 (de) 2007-02-22 2012-04-04 Genentech, Inc. Verfahren für den Nachweis von entzündlicher Darmerkrankung
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
EP2703011A2 (de) 2007-05-07 2014-03-05 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
EP2737907A2 (de) 2007-05-07 2014-06-04 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2009101479A2 (en) 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
EP2592156A2 (de) 2007-06-08 2013-05-15 Genentech, Inc. Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
EP2980100A1 (de) 2007-06-08 2016-02-03 Australian Poultry CRC Pty Ltd Clostridium toxin netb
EP4335863A2 (de) 2007-07-09 2024-03-13 Genentech, Inc. Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
EP2586788A1 (de) 2007-07-09 2013-05-01 Genentech, Inc. Verhindern der Disulfid-Bindungsreduktion während der rekombinanten Herstellung von Polypeptiden
EP4365189A2 (de) 2007-07-09 2024-05-08 Genentech, Inc. Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
EP3327026A1 (de) 2007-07-09 2018-05-30 Genentech, Inc. Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
EP4219522A2 (de) 2007-07-09 2023-08-02 Genentech, Inc. Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
EP4245766A2 (de) 2007-07-09 2023-09-20 Genentech, Inc. Verhinderung der disulfidbindungsreduktion während der rekombinanten herstellung von polypeptiden
EP2502937A2 (de) 2007-07-16 2012-09-26 Genentech, Inc. Anti-CD 79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
EP2474557A2 (de) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
EP2641618A2 (de) 2007-07-16 2013-09-25 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
WO2009046123A2 (en) 2007-10-02 2009-04-09 Genentech, Inc. Nlrr-1 antagonists and uses thereof
EP3360567A1 (de) 2007-11-07 2018-08-15 Genentech, Inc. Amp zur verwendung in der behandlung von mikrobiellen erkrankungen
EP2261367A2 (de) 2007-11-29 2010-12-15 Genentech, Inc. Expressionsmarker für entzündliche darmkrankheiten
EP3189831A1 (de) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Proteinformulierungen und verfahren zur herstellung davon
EP2851372A1 (de) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF-Antikörper
EP3173425A1 (de) 2007-11-30 2017-05-31 Genentech, Inc. Anti-vegf-antikörper
EP3524619A1 (de) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antikörper gegen influenzavirus und verfahren zur verwendung davon
EP3333187A1 (de) 2007-12-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Antikörper gegen influenzavirus und verfahren zur verwendung davon
EP3587450A1 (de) 2007-12-17 2020-01-01 Pfizer Limited Behandlung von interstitieller cystitis mit ngf inhibitoren
WO2009079649A1 (en) 2007-12-18 2009-06-25 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP3722317A1 (de) 2008-01-15 2020-10-14 The Board of Trustees of the Leland Stanford Junior University Marker für stammzellen der akuten myeloischen leukämie
EP4160212A1 (de) 2008-01-15 2023-04-05 The Board of Trustees of the Leland Stanford Junior University Marker für stammzellen der akuten myeloischen leukämie
EP3043181A1 (de) 2008-01-15 2016-07-13 The Board of Trustees of The Leland Stanford Junior University Marker für stammzellen von akuter myeloischer leukämie
EP4119583A1 (de) 2008-01-30 2023-01-18 Genentech, Inc. Zusammensetzung mit einem an her2-domäne ii bindenden antikörper und saure varianten davon
EP3401335A1 (de) 2008-01-30 2018-11-14 Genentech, Inc. Zusammensetzung mit einem an her2-domäne ii bindenden antikörper und saure varianten davon
EP2657253A2 (de) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b-Antikörper und Immunokonjugate sowie Verwendungsverfahren
EP3605088A1 (de) 2008-04-09 2020-02-05 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP3208612A1 (de) 2008-04-09 2017-08-23 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
WO2009140684A2 (en) 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
EP3321283A1 (de) 2008-06-13 2018-05-16 Pfizer Inc Behandlung von chronischer prostatitis
EP3301116A1 (de) 2008-08-25 2018-04-04 Dana Farber Cancer Institute, Inc. Konserviertes influenzahämagglutininepitop und antikörper dagegen
EP4071169A2 (de) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Konserviertes influenza-hemagglutinin-epitop und antikörper dafür
EP3211008A1 (de) 2008-08-29 2017-08-30 F. Hoffmann-La Roche AG Kreuzreaktive und bispezifische anti-il-17a/f-antikörper
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
WO2010029513A2 (en) 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists
EP3095463A2 (de) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Verfahren zur behandlung von progressiver multipler sklerose
EP3747464A1 (de) 2008-09-16 2020-12-09 F. Hoffmann-La Roche AG Verfahren zur behandlung von progressiver multipler sklerose mittels eines antikoerpers gegen cd20
EP2927244A1 (de) 2008-09-19 2015-10-07 MedImmune, LLC Gegen DLL4 gerichtete Antikörper und ihre Verwendung
EP3524620A1 (de) 2008-10-14 2019-08-14 Genentech, Inc. Immunglobulinvarianten und ihre verwendung
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3318573A1 (de) 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Immunglobulinvarianten mit veränderter bindung an protein a
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP3323427A1 (de) 2009-03-17 2018-05-23 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP3260136A1 (de) 2009-03-17 2017-12-27 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP4085925A1 (de) 2009-03-17 2022-11-09 International AIDS Vaccine Initiative Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP2679600A1 (de) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3-Antikörper und Verwendungsverfahren dafür
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
EP2584049A2 (de) 2009-07-20 2013-04-24 Genentech, Inc. Genexpressionsmarker für Morbus Crohn
EP2757160A2 (de) 2009-07-20 2014-07-23 Genentech, Inc. Genexpressionsmarker für Morbus Crohn
WO2011011339A1 (en) 2009-07-20 2011-01-27 Genentech, Inc. Gene expression markers for crohn's disease
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
EP3309168A1 (de) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Verfahren für verbesserte virenentfernung bei der proteinaufreinigung
WO2011031397A1 (en) 2009-08-06 2011-03-17 Genentech, Inc. Method to improve virus removal in protein purification
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
EP3760712A1 (de) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Herstellung von proteinen in glutamin-freien zellkulturmedien
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
EP3736338A1 (de) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Verbesserte proteinreinigung durch eine modifizierte protein-a-elution
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011046515A1 (en) 2009-10-14 2011-04-21 Nanyang Technological University Antiproliferative agent
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
EP3348277A1 (de) 2009-11-20 2018-07-18 The Regents of The University of California Epithelialmembranenprotein-2 (emp2) und proliferative vitreoretinopathie (pvr)
EP3279215A1 (de) 2009-11-24 2018-02-07 MedImmune Limited Gezielte bindemittel gegen b7-h1
EP3002297A2 (de) 2009-11-30 2016-04-06 F. Hoffmann-La Roche AG Antikörper zur behandlung und der diagnose slc34a2 (tat211) exprimierender tumore
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
EP3616719A1 (de) 2009-12-21 2020-03-04 F. Hoffmann-La Roche AG Antikörperformulierung
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
EP3450459A2 (de) 2009-12-28 2019-03-06 OncoTherapy Science, Inc. Anti-cdh3-antikörper und verwendungen davon
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP4219560A2 (de) 2010-02-18 2023-08-02 The Regents of The University of California Integrin alpha v beta 8 neutralisierender antikörper
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011104687A1 (en) 2010-02-24 2011-09-01 Rinat Neuroscience Corporation Antagonist anti-il-7 receptor antibodies and methods
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2011119888A2 (en) 2010-03-24 2011-09-29 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2011123507A1 (en) 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP3299380A1 (de) 2010-05-25 2018-03-28 F. Hoffmann-La Roche AG Verfahren zur aufreinigung von polypeptiden
WO2011150110A1 (en) 2010-05-25 2011-12-01 Genentech, Inc. Methods of purifying polypeptides
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
EP3327039A1 (de) 2010-06-02 2018-05-30 Dana Farber Cancer Institute, Inc. Humanisierte monoklonale antikörper und verfahren zu ihrer verwendung
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2011159655A2 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP3323830A1 (de) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anti-gd2-antikörper
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
WO2012027723A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc Notum protein modulators and methods of use
EP3556396A1 (de) 2010-08-31 2019-10-23 Theraclone Science, Int. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP4085924A1 (de) 2010-08-31 2022-11-09 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP4226935A2 (de) 2010-08-31 2023-08-16 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
EP2926830A2 (de) 2010-08-31 2015-10-07 Theraclone Sciences, Inc. Antikörper zur Neutralisierung des humanen Immundefizienz-Virus (HIV)
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012058768A1 (en) 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
WO2012078813A2 (en) 2010-12-08 2012-06-14 Stem Centrx, Inc. Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012112943A1 (en) 2011-02-18 2012-08-23 Stem Centrx, Inc. Novel modulators and methods of use
EP3763388A1 (de) 2011-02-18 2021-01-13 AbbVie Stemcentrx LLC Neuartige modulatoren und verfahren zur verwendung
WO2012125614A1 (en) 2011-03-15 2012-09-20 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP3412309A1 (de) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Verfahren zur verabreichung von beta7-integrin-antagonisten
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP3527274A1 (de) 2011-11-02 2019-08-21 F. Hoffmann-La Roche AG Überstrom- und elutionschromatographie
WO2013067301A1 (en) 2011-11-02 2013-05-10 Genentech, Inc. Overload and elute chromatography
EP3257564A1 (de) 2011-11-02 2017-12-20 F. Hoffmann-La Roche AG Überladung- und elutionschromatographie
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013068946A2 (en) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2013093707A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3663314A1 (de) 2012-01-09 2020-06-10 The Scripps Research Institute Humanisierte antikörper mit ultralangem cdr3s
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3578569A1 (de) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
EP3095797A1 (de) 2012-02-24 2016-11-23 Stemcentrx, Inc. Dll3-antikörper und verfahren zur verwendung
WO2013149111A2 (en) 2012-03-29 2013-10-03 Novimmune S.A. Anti-tlr4 antibodies and uses thereof
EP3511343A1 (de) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinitätsgereifte humanisierte monoklonale anti-ccr4-antikörper und verfahren zur verwendung
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
EP3498857A1 (de) 2012-06-11 2019-06-19 Amgen, Inc. Proteine zur bindung antagonistischer antigene mit zwei rezeptoren und verwendungen davon
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
EP3540070A1 (de) 2012-06-11 2019-09-18 Amgen Inc. Proteine zur bindung antagonistischer antigene mit zwei rezeptoren und verwendungen davon
WO2014018554A1 (en) 2012-07-23 2014-01-30 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
EP3401337A1 (de) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Reinigung von hetero-dimeren immunglobulinen
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
EP3725807A1 (de) 2012-12-03 2020-10-21 NovImmune SA Anti-cd47-antikörper und verfahren zur verwendung davon
WO2014087248A2 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
EP4137518A1 (de) 2013-02-06 2023-02-22 Inhibrx, Inc. Nicht-plättchen-depletierende und nicht-erythrozyten-depletierende cd47-antikörpern und verfahren zur verwendung davon
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
WO2014130064A1 (en) 2013-02-22 2014-08-28 Abbvie Inc. Ultrafiltration and diafiltration formulation methods for protein processing
EP3556400A1 (de) 2013-02-22 2019-10-23 AbbVie Stemcentrx LLC Methode zur herstellung von antidll3-antikörper pbd konjugaten
EP3744345A1 (de) 2013-03-13 2020-12-02 F. Hoffmann-La Roche AG Antikörperformulierungen
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
EP4292657A2 (de) 2013-03-15 2023-12-20 Dana Farber Cancer Institute, Inc. Flavi-virus-neutralisierende antikörper und verfahren zur verwendung davon
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
EP3689902A1 (de) 2013-03-15 2020-08-05 Dana Farber Cancer Institute, Inc. Flavi-virus-neutralisierende antikörper und verfahren zur verwendung davon
WO2014144061A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
US10400032B2 (en) 2013-03-15 2019-09-03 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EP3712252A1 (de) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Zellkulturzusammensetzungen mit antioxidantien und verfahren zur polypeptidherstellung
US9822166B2 (en) 2013-03-15 2017-11-21 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
WO2015147915A1 (en) 2013-03-24 2015-10-01 Development Center For Biotechnology Methods for suppressing cancer by inhibition of tmcc3
EP3933401A2 (de) 2013-03-27 2022-01-05 F. Hoffmann-La Roche AG Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
EP3495814A2 (de) 2013-03-27 2019-06-12 F. Hoffmann-La Roche AG Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
WO2014172661A1 (en) 2013-04-19 2014-10-23 The Regent Of The University Of California Lone star virus
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
EP3536699A1 (de) 2013-07-12 2019-09-11 F. Hoffmann-La Roche AG Darstellung einer eingabeoptimierung in der ionenaustauschchromatografie
EP3789036A1 (de) 2013-07-16 2021-03-10 F. Hoffmann-La Roche AG Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und tigit-inhibitoren
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3705494A2 (de) 2013-08-14 2020-09-09 Sachdev Sidhu Antikörper gegen frizzled proteine und verwendung davon
EP3892294A1 (de) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
EP3338793A1 (de) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Neuartige sez6-modulatoren und verfahren zur verwendung
WO2015031837A1 (en) 2013-08-29 2015-03-05 City Of Hope Cell penetrating conjugates and methods of use thereof
EP3626742A1 (de) 2013-09-27 2020-03-25 F. Hoffmann-La Roche AG Anti-pdl1-antikörper-formulierungen
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
EP3176185A1 (de) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Herstellung von t-zellen zum retargeting von heterodimeren immunglobulinen
WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015084625A1 (en) 2013-12-02 2015-06-11 Baylor College Of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
EP3527587A1 (de) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Kombinationstherapie mit ox40-bindungsagonisten und pd-l1-bindungsantagonisten
WO2015095418A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3647324A1 (de) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindenden antagonisten und taxanen
EP3680254A1 (de) 2013-12-17 2020-07-15 F. Hoffmann-La Roche AG Verfahren zur behandlung von her2-positiven karzinomen mit pd-1 bindungsantagonisten und anti-her2-antikörpern
EP4043493A1 (de) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
EP3712174A1 (de) 2013-12-24 2020-09-23 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP4043489A1 (de) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immungenetische beschränkung der elazitation von antikörpern
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP4324481A2 (de) 2014-03-21 2024-02-21 Teva Pharmaceuticals International GmbH Antagonistische antikörper gegen calcitonin-gen-assoziiertes peptid und verfahren zur verwendung davon
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2015161267A2 (en) 2014-04-18 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
EP3613433A1 (de) 2014-05-30 2020-02-26 Henlix Biotech Co., Ltd. Antikörper gegen den epidermalen wachstumsfaktor-rezeptor (egfr)
WO2015195835A2 (en) 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
EP4285917A2 (de) 2014-06-18 2023-12-06 Mersana Therapeutics, Inc. Monoklonale antikörper gegen her2-epitop und verfahren zur verwendung davon
WO2015195917A1 (en) 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Monoclonal antibodies against her2 epitope and methods of use thereof
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3699196A1 (de) 2014-10-06 2020-08-26 Dana Farber Cancer Institute, Inc. Humanisierte antikörper des cc-chemokin-rezeptors 4 (ccr4) und verfahren zur verwendung davon
EP3753948A1 (de) 2014-11-05 2020-12-23 Genentech, Inc. Verfahren zur herstellung von zweikettigen proteinen in bakterien
WO2016073794A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016092419A1 (en) 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof
EP4166572A1 (de) 2014-12-09 2023-04-19 Rinat Neuroscience Corp. Anti-pd-1-antikörper und verfahren zu deren verwendung
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
EP3733696A1 (de) 2015-01-13 2020-11-04 City of Hope Peptid-linkermasken mit ctla4-bindenden proteinen
EP3795168A1 (de) 2015-01-16 2021-03-24 City of Hope Zellendurchdringende antikörper
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
EP3978530A1 (de) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin-beta7-antagonisten und verfahren zur behandlung von morbus crohn
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
US10011658B2 (en) 2015-04-03 2018-07-03 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
WO2016164835A1 (en) 2015-04-08 2016-10-13 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
WO2016166629A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Therapeutic antibodies and their uses
EP3988117A1 (de) 2015-04-13 2022-04-27 Pfizer Inc. Therapeutische antikörper und deren verwendungen
EP4234581A2 (de) 2015-04-13 2023-08-30 Pfizer Inc. Therapeutische antikörper und deren verwendungen
WO2016178779A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
EP3842448A1 (de) 2015-05-15 2021-06-30 City of Hope Chimäre antigenrezeptorzusammensetzungen
EP3447075A2 (de) 2015-05-15 2019-02-27 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
EP4292664A2 (de) 2015-05-15 2023-12-20 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
EP3763827A1 (de) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1-promotormethylierung bei krebs
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
WO2017024238A1 (en) 2015-08-06 2017-02-09 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
WO2017041004A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
EP4223784A2 (de) 2015-09-02 2023-08-09 The Regents of the University of Colorado, a body corporate Zusammensetzungen und verfahren zur modulation der t-zell-vermittelten immunantwort
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017100714A1 (en) 2015-12-10 2017-06-15 City Of Hope Cell penetrating cyanine-coupled antibodies
WO2017112917A1 (en) 2015-12-24 2017-06-29 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
EP3862365A1 (de) 2016-01-08 2021-08-11 F. Hoffmann-La Roche AG Verfahren zur behandlung von cea-positiven karzinomen unter verwendung von antagonisten mit pd-1-achsen-bindung und bispezifischen anti-cea-/anti-cd3-antikörpern
WO2017125831A1 (en) 2016-01-21 2017-07-27 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017173302A2 (en) 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017218977A2 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
WO2018018039A2 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
CN106079858A (zh) * 2016-08-03 2016-11-09 钟晴晴 一种丝网印刷机
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035025A1 (en) 2016-08-15 2018-02-22 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018048939A1 (en) 2016-09-06 2018-03-15 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
EP4339615A2 (de) 2016-09-16 2024-03-20 Shanghai Henlius Biotech, Inc. Anti-pd-1-antikörper
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2018055573A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018064478A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
WO2018064436A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
WO2018083535A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
WO2018093841A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il-23 specific antibody
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2018194496A2 (ru) 2017-04-17 2018-10-25 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
US11236167B2 (en) 2017-04-17 2022-02-01 Joint Stock Company “Biocad” Monoclonal antibody to PD-L1
EP4230649A2 (de) 2017-04-25 2023-08-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2018209194A2 (en) 2017-05-12 2018-11-15 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
WO2019070164A1 (ru) 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
WO2019171252A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2019178248A1 (en) 2018-03-13 2019-09-19 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
WO2019175658A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
US11241417B2 (en) 2018-06-21 2022-02-08 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006568A1 (en) 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
WO2020018789A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
EP4249917A2 (de) 2018-09-21 2023-09-27 F. Hoffmann-La Roche AG Diagnosemethoden für dreifach-negativen brustkrebs
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
WO2020096959A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
WO2020213724A1 (ja) 2019-04-19 2020-10-22 中外製薬株式会社 抗体改変部位認識キメラ受容体
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2020247634A1 (en) 2019-06-05 2020-12-10 Genentech, Inc. A method for regeneration of an overload chromatography column
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
WO2021021605A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
WO2021163265A1 (en) 2020-02-11 2021-08-19 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
EP4356924A2 (de) 2020-03-26 2024-04-24 Vanderbilt University Menschliche monoklonale antikörper gegen schweres akutes respiratorisches syndrom coronavirus 2 (sars-cov-2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021222935A2 (en) 2020-04-28 2021-11-04 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022159349A1 (en) 2021-01-20 2022-07-28 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
WO2022190033A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022190034A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2022200389A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022200387A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023081471A1 (en) 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023187407A1 (en) 2022-04-01 2023-10-05 Bradcode Limited Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
WO2023192622A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Also Published As

Publication number Publication date
FR2413974A1 (fr) 1979-08-03
FR2413974B1 (de) 1982-12-03
EP0003089B1 (de) 1981-08-12
DE2860970D1 (en) 1981-11-12

Similar Documents

Publication Publication Date Title
EP0003089B1 (de) Trockner für durch Siebdruck bedruckte Bogen
CH675784A5 (de)
EP0039526B1 (de) Transportvorrichtung zur Überführung von frisch bedruckten Bogen
EP0286514B1 (de) Förderer mit Platten, die insbesondere den Transport von Behältern gestatten
EP0424290B1 (de) Vorrichtung zum Positionieren eines Produkts in Form eines flexiblen Tuches
BE1004555A3 (fr) Machine pour decouenner du lard.
EP0780065A1 (de) Montiermaschine für Oberteil und Sohle eines Schuhes
FR2518495A1 (fr) Dispositif d'emballage dans des sacs, notamment pour ensachage de jambons
EP0425400A1 (de) Verfahren und Vorrichtung zum Zusammenbinden von GeflÀ¼gel
FR2541562A1 (fr) Procede de greffage automatique de la vigne et machine comportant application de ce procede
EP0086867B1 (de) Tragbare Etikettiermaschine
EP0220967B1 (de) Transportvorrichtung für Behälter
EP0578551B1 (de) Verbesserungen in Druckmaschinen, insbesondere für Sieb- druckmaschinen
CH642269A5 (fr) Frein a ski.
BE1004855A5 (fr) Mecanisme d'avancement de feuille en rouleau pour machine a dessiner automatique du type a entrainement de papier.
FR2575629A1 (fr) Dispositif de montage automatique sur un substrat d'elements de circuit du type puce
EP0320342B1 (de) Abkantbank
EP0252844B1 (de) Automatische Vorrichtung zum Bearbeiten, insbesondere zum Schneiden von Bändern
FR2733491A1 (fr) Dispositif de sortie d'exemplaires imprimes d'un dispositif a roues a aubes
FR2724294A1 (fr) Machine pour le bridage des volailles
BE1001017A6 (fr) Procede pour fixer l'extremite libre d'un rouleau de matiere plastique et dispositif pour la mise en oeuvre de ce procede.
EP0219444B1 (de) Holzspaltgerät mit drehendem Spaltkegel
CH370005A (fr) Machine à poser des agrafes pour la fermeture de sacs
FR2579562A1 (fr) Dispositif pour la mise en place d'un manchon etirable sur un bidon
CH402388A (fr) Appareil pour le façonnage d'articles à partir d'une feuille thermoplastique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

17P Request for examination filed
ITF It: translation for a ep patent filed

Owner name: ST. ASSOC. MARIETTI & PIPPARELLI

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

REF Corresponds to:

Ref document number: 2860970

Country of ref document: DE

Date of ref document: 19811112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19811231

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: SVECIA SILKSCREEN MASKINER AB

Effective date: 19820218

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: LINDBLOM, ERIK J.

Effective date: 19820218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19831031

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19831130

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19831231

Year of fee payment: 6

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841221

Year of fee payment: 7

Ref country code: CH

Payment date: 19841221

Year of fee payment: 7

27O Opposition rejected

Effective date: 19840722

NLR2 Nl: decision of opposition
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19851231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19861231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19870701

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19871228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19871231

BERE Be: lapsed

Owner name: SILIUM S.F.A.R.L.

Effective date: 19871231

Owner name: DAVID BERNARD

Effective date: 19871231

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78400265.1

Effective date: 19880912